Quick Answer
Avalo Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $59.0 thousand for the year ending 2025.
- Avalo Therapeutics, Inc. showed a decrease of -86.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $157.8 thousand | Q3 2017: $25.04 million | Q1 2018: $4.48 million | Q2 2018: $4.79 million | Q3 2018: $4.07 million | Q1 2019: $2.58 million | Q2 2019: $1.39 million | Q3 2019: $2.20 million | Q1 2020: $2.75 million | Q2 2020: $1.34 million | Q3 2020: $1.11 million | Q1 2021: $473.0 thousand | Q2 2021: $3.36 million | Q3 2021: $1.35 million | Q1 2022: $1.17 million | Q2 2022: $1.03 million | Q3 2022: $14.95 million | Q1 2023: $475.0 thousand | Q2 2023: $643.0 thousand | Q3 2023: $236.0 thousand | Q1 2024: $0.00 | Q2 2024: $0.00 | Q3 2024: $249.0 thousand | Q3 2025: $0.00.
- Over the full 9 years of available data (2017 to 2025), Avalo Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 99.8%.
- Historical annual values: Fiscal year 2025: $59.0 thousand | Fiscal year 2024: $441.0 thousand | Fiscal year 2023: $1.92 million | Fiscal year 2022: $18.05 million | Fiscal year 2021: $5.40 million | Fiscal year 2020: $6.70 million | Fiscal year 2019: $6.75 million | Fiscal year 2018: $7.03 million | Fiscal year 2017: $27.81 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: